Biochemical Evaluation of Antitumor Activity of Vitamin B17 Alone or in Combination with Platinum Based Drugs Against Ehrlich Ascites Carcinoma in Female Rats

*Veterinarian; **Biochemistry department, Faculty of Veterinary Medicine, Suez Canal University
*Corresponding author: Email: ashraf.biochemistry@gmail.com Tel.: +201140000974

Abstract
Chemotherapeutic agents are associated with many side effects. Consequently, much research is interested in the discovery of natural phytochemical compounds that can be used in the prevention and/or treatment of cancer. Ehrlich ascites carcinoma (EAC) model was used to indicate the effectiveness of some chemotherapy and plant sources against cancer due to its similarity with human tumors. The present study was undertaken to investigate antitumor and antioxidant effects of vitamin B17 beside platinum-based drugs in EAC-bearing female rats. Animals were randomly distributed into seven groups (n=7) as follows: Group A, negative control. Group B, positive control that was injected by EAC cells as a cancer model. Group C, EAC-bearing rats were treated with cisplatin. Group D, rats with EAC and were treated by a single dose of oxaliplatin. Group E, rats with EAC and were treated with vitamin B17 (VB17). Group F, rats with EAC and were treated with cisplatin plus vitamin B17. Group G, EAC-bearing rats that were treated by single-dose oxaliplatin plus VB17. One week after the beginning of treatments, blood samples were collected and tumor markers (AFP, CEA, CA19-9, TPA, and LDH), as well as antioxidants biomarkers (SOD, CAT, GSH, and MDA), were measured. Liver and kidney functions were evaluated. Besides, histopathological examination was performed to evaluate antitumor activity and side effects of used drugs on hepatic and renal tissues. Results showed that administration of VB17 alone or in combination with cisplatin or oxaliplatin led to a decrease of tumor markers together with enhancement of antioxidant indicators compared with EAC-bearing rats. Statistical analysis showed a significant
(P<0.05) increase in the activities of ALT, AST, ALP accompanied by an increase in the serum levels of creatinine, BUN, and total bilirubin in cisplatin and oxaliplatin treated groups, thus confirming their toxic effects on hepatocytes and renal cells. These findings were supported by histopathological alterations in these groups. VB17 treated groups showed improvement in the studied parameters. From the current study, it could be concluded that vitamin B17 possesses anticancer and antioxidant activities that justify its traditional use, and its potential hepatoprotective effect and kidney ameliorative role.

**Keywords:** Ehrlich ascites carcinoma, Vitamin B17, Cisplatin, Oxaloplatin, Tumour markers, Antioxidants.

**Introduction**

Many plants and phytochemicals exhibit valuable antioxidant activities, which have a significant role in the treatment and prevention of cancer (Abd Eldaim et al., 2019b; Elmasry et al., 2018; Oyouni et al., 2018). Vitamin B17 (VB17), also termed amygdalin and laetrile, is a cyanogenic diglucoside, a type of carbohydrate that is mostly naturally found in the kernel of fruits such as apricot, bitter almond, macadamias, and peach. Many researchers reported that VB17 has numerous medicinal activities including antitussive, anti-asthmatic, antiatherogenic, anticancer, anti-inflammation, and anti-ulcer potentials beside its ability to inhibit fibrosis (Juengel et al., 2016; Makarević et al., 2016; Qian et al., 2015). Also, some studies have supported that VB17 can induce apoptotic cell death of several cancer types such as promyelocytic leukemia, cervical, prostatic and hepatic cancer (Chen et al., 2013; Sauer et al., 2015; Zhou et al., 2012).

Various malignancies could be treated by using platinum-based drugs such as cisplatin, oxaliplatin, and carboplatin alone or in combination with other chemotherapeutic agents (Wong and Giandomenico, 1999). Cisplatin [cisdiaminedichloroplatinum (II), CDDP], is the first compound of this group. It blocks DNA replication and RNA transcription which initiates apoptosis process (Wang and Lippard, 2005). Its application is still limited due to the side-effects associated with its toxicity as well as increasing cisplatin resistant (Brabec and Kasparkova, 2005).
Oxaliplatin is a third-generation platinum-based drug with 1,2-diaminocyclohexane (DACH) substituting the amine groups of cisplatin (Raymond et al., 2002). It has demonstrated a satisfied safety profile, characterized by low haematotoxicity, fewer inter and intra DNA strands adducts to achieve the same cytotoxicity. The main side effect of this compound is neurotoxicity (Waseem et al., 2017).

Ehrlich ascites carcinoma (EAC) is an undifferentiated, rapidly proliferative, short life span, 100% malignance spontaneous murine breast adenocarcinoma (Kaleoğlu and İşi, 1977). It is firstly observed in a female mouse, then extensively studied afterwards using murine models, including mice (Mishra et al., 2018; Sugiura, 1953; Wang, 2013) and rat (Olinici et al., 1975, 1977; Osman et al., 2015; Podoplelov, 1957) to a lesser extent, to investigate tumor pathogenesis and development of anti-tumorigenic agents (Simon et al., 1979) due to its resemblance to human tumors since it is highly sensitive to chemotherapy with rapid growth rates, great transplantable capability and lacks tumor-specific transplantation antigen (TSTA) (Ozaslan et al., 2011). Loewenthal and Jahn (1932) named it as “Ehrlich ascites carcinoma” due to development of the ascites liquid, with carcinoma cells in peritoneum of mouse after intraperitoneal (i.p) injection of cells.

The current study aimed to investigate antioxidant and antitumor activities of VB17 on EAC - bearing female rats alone and in combination with cisplatin or oxaliplatin to ameliorates their side effects on hepatic and renal tissues.

Material and Methods
Experimental animals:
A total number of 49 female healthy albino rats weighing 120–130 g were used in the current study. They were obtained from the animal laboratory house in Faculty of Veterinary Medicine, Suez Canal University. The animals were housed in plastic cages and maintained under controlled conditions of temperature (23–25 °C), relative humidity (40–70%) and diurnal environmental (12 h light/dark cycles). All animals had free access to water and standard laboratory rat diet during the experimental period. Rats were acclimatized for seven days before starting the experiment. This study was approved by committee of scientific research and biological ethics for animals used in laboratory experiments in the Faculty of Veterinary
Said et al. Medicine, Suez Canal University, Egypt.

Drugs:
1- Platinol® (cisplatin for injection, USP) is a white to light yellow lyophilized powder. Imported by RAMCO, Manufacturer: Oncotec Pharma Produktion GmbH – Germany.

2- Oxaliplatin (Eloxatin) is a white to off-white powder or crystals, is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone. Imported by Forward Pharma Co. EGY.

3- Vitamin B17 (VB17, Amygdalin) chemical name: [(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl) oxy] (phenyl) acetonitrile. Produced by Cytopharma de Mexico, S.A

Tumor cell line (Induction stage):
The parent line of Ehrlich ascites carcinoma cells (EAC cells) was obtained from the National Cancer Institute (NCI), Cairo University, Egypt. EAC cells were collected from donor female Swiss albino mice of 18 – 20 g body weight and suspended in sterile saline (0.9% NaCl). A fixed number of viable cells (usually 2.5×10⁶ cells/mice) were implanted in the peritoneal cavity of each recipient female rat (Salem et al., 2011). Every 0.5 ml of EAC was withdrawn by a sterile disposable syringe, diluted with 4.5ml of normal saline (0.9% NaCl). 0.2 ml of diluted EAC was i.p. injected into 42 rats. The tumor cells were allowed to multiply within the peritoneal cavity for 2 weeks (Abouzaid, 2013; Hanafy, 2009).

Experimental Design:
Animals were randomly divided into seven groups, seven animals each as follow:

Group A (negative control) served as normal control group. Rats were treated with saline and received standard diet all over the experimental period (3 weeks).

Group B (positive control) served as EAC control group. Rats were i.p. injected by EAC cells and were not treated all over the experimental period (3 weeks).

Group C (Cisplatin) served as EAC + cisplatin group. Rats were i.p. injected by EAC cells. Two weeks after the induction phase, the animals were i.p. treated with cisplatin (12 mg/kg b.w.) for one week (Miller et al., 2010). Group D (Oxaliplatin) served as EAC + oxaliplatin group. Rats were i.p. injected by EAC cells. Two weeks after the induction phase, the animals were treated with a single i.p. injection of oxaliplatin (6 mg/kg) (Ling et al., 2008).

Group E (Vitamin B17) served as EAC + VB17 group. Rats were i.p. injected by EAC cells.
Two weeks after the induction phase, the animals were i.p. treated with VB17 (4 mg/kg) for one week (Minaiyan et al., 2014).

**Group F (Cisplatin + Vitamin B 17)** served as EAC + cisplatin + VB17 group. Rats were i.p. injected by EAC cells. Two weeks after the induction phase, the animals were i.p. treated cisplatin (12 mg/kg b.w.) and VB17 (4 mg/kg) for one week.

**Group G (Oxaliplatin + Vitamin B 17)** served as EAC + oxaliplatin + VB17 group. Rats were i.p. injected by EAC cells. Two weeks after the induction phase, the animals were treated with single i.p. injection of oxaliplatin (6 mg/kg) and VB17 (4 mg/kg) for one week.

**Blood and tissue samples collection:**
At the end of the experiment (one week after starting treatments), blood samples were collected from overnight fasted rats from retro orbital venous plexus using micro-hematocrit tubes under the effect of light ether anesthesia. Blood was divided into two tubes; EDTA and plain centrifuge tubes for determination of hematological and biochemical parameters, respectively. Clear serum samples were separated and stored at -20°C till time of analysis. Liver, kidney and spleen were collected and fixed in 10% formalin for histopathological examinations.

**Evaluation of hematological parameters:**
Hematological parameters were determined by automated hematology system analyzer using whole blood. The assessed parameters include total and differential white blood cells count (WBC), red blood cells count (RBC), hemoglobin (Hb), hematocrit (HCT), mean cell volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC) and platelets.

**Evaluation of biochemical parameters:**
- **Determination of tissue antioxidants**
Catalase (CAT) (Sigma-Aldrich Co., USA) and superoxide dismutase (SOD) activities, reduced Glutathione (GSH) and malondialdehyde (MDA) were calorimetrically measured using methodology described by (Aebi, 1984; Fossati et al., 1980), (Nishikimi et al., 1972), (Beutler and Gelbart, 1985) and (Satoh, 1978).
- **Determination of tumor markers:**
Tumor markers, including alpha-fetoprotein (Mcintire et al., 1975; Tatarinov, 1964), carcinoembryonic antigen (CEA) (Thomson et al., 1969; Zamcheck and Martin, 1981), carbohydrate antigen 19-9
(Koprowski et al., 1981), tissue polypeptide antigen (TPA) (Björklund and Björklund, 1957) (LDH), and lactate dehydrogenase (LDH) (Lorentz et al., 1993), were estimated using kits manufacturer protocol.

- Determination of liver and kidney functions
  Serum activities of alanine amino transferase (ALT), aspartate amino transferase (AST) and alkaline phosphatase (ALP) (Human, Germany) were assayed using the method of (Schumann and Klauke, 2003) and (Moss and Henderson, 1999), respectively. Serum total proteins, albumin, creatinine and blood urea nitrogen (BUN) levels were assayed using methodology described by El-Moghazy et al. (2014), Moustafa et al. (2014), Jaffé (1886) and Chaney and Marbach (1962), respectively.

Histopathological Evaluation:
Organs were processed by standard methods to prepare slides of hepatic, renal and spleen tissues by hematoxylin and eosin (H&E) staining (El-Sayyad et al., 2009; Ray et al., 1981). Then, slides were viewed under light microscope.

Statistical analysis:
All data were subjected to statistical analysis by using computer programs, SPSS version 18 for analysis of data and Duncan’s multiple range test for determination of LSD. Comparison were carried by means using analysis of variance "F test" (ANOVA) where appropriate statistical significance was calculated using least significant difference "LSD". The level of statistical significance was taken as P < 0.05.

Results
Macroscopic observations
After inoculation of rats with EAC cells, rats exhibited marked enlargement of abdomen with formation of ascitic fluid (Figure 1).

parameters
Results showed significant (P<0.05) decrease in RBCs count, Hb level, PCV, MCV, MCH, MCHC as well as PLT count in EAC bearing rats (group B) with significant (P<0.05) increase in WBCs count when compared with the control group (group A). On the other hand, treating EAC-bearing rats with either VB17 alone (group E) or in combination with oxaliplatin (group G) resulted in a significant (P<0.05) improvement in previous parameters when compared with other treated groups (groups C, D and F) (Table 1).

Effect of cisplatin, oxaloplatin and VB17 on antioxidant parameters:
The effect of cisplatin, oxaloplatin and VB17 on antioxidant status (SOD, CAT, GSH and MDA) of EAC bearing rats are shown in Table (2). Antioxidant enzymes activities (SOD and CAT) as well as GSH level were significantly (P<0.05) reduced in EAC-induced rats (Groups B, C and D) compared to the control group (Group A) whereas MDA level was significantly (P<0.05) elevated. However, treating rats with VB17 either alone or in combination with cisplatin or oxaloplatin improved antioxidant status of rats.

Effect of cisplatin, oxaloplatin and VB17 on tumor biomarkers
Table (3) showed EAC bearing rats (group B) exhibited significant (P<0.05) elevation in serum levels of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA 19-9), tissue polypeptide antigen (TPA) and lactate dehydrogenase (LDH) activity as compared with normal rats (group A). On the other hand, treatment of rats with cisplatin (group C), oxaloplatin (group D), VB17 (group E), or their combinations (groups F and G) resulted in significant (P<0.05) reduction in serum tumor markers. Moreover, the best results were observed in groups E and G.

Effect of cisplatin, oxaloplatin and VB17 on liver functions
As shown in Table (4), EAC bearing rats (group B, C and D) demonstrated a significant (P<0.05) rise in activity of hepatic enzymes (ALT, AST and ALP) in serum meanwhile serum albumin and total bilirubin levels were significantly (P<0.05) decreased when compared with normal rats (group A). In contrast, treatment of rats VB17 alone or coincided with oxaloplatin (group E, G) resulted in a significant (P<0.05) improvement in hepatic markers.

Effect of Cisplatin, Oxaloplatin and VB17 on kidney function
Results shown in Table (5) demonstrated that rats of group (B, C and F) developed significant (P<0.05) elevation in serum creatinine and BUN levels as compared with the control rats (group A). While rats of groups (D, E and G) showed a significant reduction in serum creatinine and BUN levels.

Effect of cisplatin, oxaloplatin and VB17 on hepatic, splenic and renal tissues:
Liver sections of rat bearing Ehrlich ascites carcinoma (Group B) showed various histopathological alternations.
including vacuolization of hepatocellular cytoplasm, sporadic cell necrosis of individual hepatocytes with deeply pyknotic nuclei, congestion of central vein. EAC bearing rats treated with cisplatin (Group C) showed congested portal tract vessel and hydropic degeneration of hepatocytes while treated with oxaliplatin (Group D) showed uniform hepatocytes, with congested central vein. EAC bearing rats and treated with VB17 (Group E) showed uniform hepatocytes with no signs of injury. EAC bearing rats and treated with VB17 (Group E) showed uniform hepatocytes with no signs of injury. EAC bearing rats and treated with cisplatin plus VB17 (Group F) showed hydropic degeneration of hepatocytes, patent sinusoids with congested portal vessel. EAC bearing rats and treated with oxaliplatin plus VB17 (Group G) showed uniform hepatocytes, with mildly congested sinusoids (Figure 2).

While spleen sections of rats bearing EAC (Group B) showed marked expansion of red bulb due to congestion and small uniform lymphoid follicles. In EAC bearing rats and rats treated with cisplatin (Group C) or with oxaliplatin (Group D) spleen sections showed expansion of red bulb due to congestion and atrophic lymphoid follicles. EAC bearing rats and treated with VB17 (Group E) showed weak expansion of red bulb due to slight congestion of lymphoid follicles. EAC bearing rats treated with cisplatin plus VB17 (Group F) or oxaliplatin plus VB17 (Group G) showed expansion of red bulb due to congestion atrophic lymphoid follicles (Figure 3).

Kidney sections of rat bearing EAC (Group B) showed enlarged glomeruli, mesangial expansion and endo-capillary proliferation. Renal tubules show increased evidence of acute tubular injury. In EAC bearing rats treated with cisplatin (Group C) as well as those treated with oxaliplatin (Group D) renal tubules showed evidence of acute tubular injury. EAC bearing rats and treated with VB17 (Group E) showed mild enlarged glomeruli with tubules in addition to evidence of mild acute tubular injury. In EAC bearing rats and treated with cisplatin plus VB17 (Group F) or oxaliplatin plus VB17 (Group G), glomeruli became enlarged with mesangial expansion and endo-capillary proliferation. Tubules showed increased evidence of acute tubular injury (Figure 4).
Figure 1: Stages of development of tumor ascitic fluid in rats
Effect of cisplatin, oxaloplatin and VB17 on hematological parameters

Table (1): Hematological Parameters in different treated groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
<th>Group E</th>
<th>Group F</th>
<th>Group G</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBCs (million/mm$^3$)</td>
<td>6.53 ± 0.13</td>
<td>5.23 ± 0.19</td>
<td>5.41 ± 0.29</td>
<td>5.79 ± 0.10</td>
<td>6.07 ± 0.07</td>
<td>5.85 ± 0.12</td>
<td>6.62 ± 0.10</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>14.24± 0.49</td>
<td>10.50± 0.41</td>
<td>10.73± 0.41</td>
<td>11.44± 0.36</td>
<td>13.21± 0.53</td>
<td>10.93± 0.22</td>
<td>12.57± 0.38</td>
</tr>
<tr>
<td>PCV (HCT) (L/L)</td>
<td>0.44± 0.005</td>
<td>0.39± 0.004</td>
<td>0.40± 0.003</td>
<td>0.41± 0.003</td>
<td>0.43± 0.003</td>
<td>0.40± 0.005</td>
<td>0.42± 0.005</td>
</tr>
<tr>
<td>MCV (fl)</td>
<td>57.00± 2.16</td>
<td>43.86± 1.32</td>
<td>45.29± 0.52</td>
<td>47.71± 0.52</td>
<td>54.71± 1.46</td>
<td>47.29± 0.52</td>
<td>50.43± 0.81</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>21.14± 0.63</td>
<td>16.86± 0.34</td>
<td>18.71± 0.52</td>
<td>19.57± 0.48</td>
<td>21.14± 0.63</td>
<td>19.29± 0.52</td>
<td>20.71± 0.52</td>
</tr>
<tr>
<td>MCHC (g/L)</td>
<td>331.43± 9.86</td>
<td>274.29± 16.81</td>
<td>278.57± 3.40</td>
<td>295.71± 4.81</td>
<td>317.14± 5.22</td>
<td>288.57± 3.40</td>
<td>311.43± 3.40</td>
</tr>
<tr>
<td>PLT (10$^9$/L)</td>
<td>832.14± 26.14</td>
<td>702.86± 16.43</td>
<td>584.29± 14.94</td>
<td>384.29± 20.22</td>
<td>795.71± 31.31</td>
<td>654.29± 16.31</td>
<td>507.14± 22.65</td>
</tr>
<tr>
<td>WBCs (10$^9$/L)</td>
<td>11.10± 0.39</td>
<td>17.00± 0.52</td>
<td>15.31± 0.68</td>
<td>13.80± 0.50</td>
<td>11.86± 0.33</td>
<td>13.96± 0.52</td>
<td>12.50± 0.55</td>
</tr>
</tbody>
</table>

All values were expressed as mean ± SE. Differences were considered significant at P<0.05.

Table (2) Antioxidant status in different treated groups

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
<th>Group E</th>
<th>Group F</th>
<th>Group G</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD (IU x 10$^4$)</td>
<td>2.29± 0.09</td>
<td>1.14± 0.08</td>
<td>1.27± 0.12</td>
<td>1.65± 0.14</td>
<td>2.20± 0.13</td>
<td>2.00± 0.15</td>
<td>2.24± 0.15</td>
</tr>
<tr>
<td>CAT (IU x 10$^3$)</td>
<td>3.54± 0.17</td>
<td>1.47± 0.17</td>
<td>1.99± 0.11</td>
<td>2.02± 0.10</td>
<td>3.40± 0.15</td>
<td>2.96± 0.12</td>
<td>3.50± 0.15</td>
</tr>
<tr>
<td>GSH (μmol/L)</td>
<td>5.53± 0.16</td>
<td>3.49± 0.12</td>
<td>3.65± 0.12</td>
<td>4.05± 0.14</td>
<td>5.56± 0.15</td>
<td>5.50± 0.16</td>
<td>5.43± 0.17</td>
</tr>
<tr>
<td>MDA (mM/L x 10$^3$)</td>
<td>3.01± 0.33</td>
<td>5.49± 0.18</td>
<td>4.86± 0.11</td>
<td>4.25± 0.24</td>
<td>2.40± 0.15</td>
<td>2.94± 0.19</td>
<td>2.80± 0.21</td>
</tr>
</tbody>
</table>

All values were expressed as mean ± SE. Differences were considered significant at P<0.05.
Table (3) **Tumor biomarkers in different treated groups**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
<th>Group E</th>
<th>Group F</th>
<th>Group G</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFB (ng/ml)</td>
<td>14.43 ± 1.70</td>
<td>60.71 ± 3.41</td>
<td>47.43 ± 2.49</td>
<td>40.14 ± 1.70</td>
<td>25.29 ± 1.64</td>
<td>42.71 ± 2.56</td>
<td>35.29 ± 1.70</td>
</tr>
<tr>
<td>CEA (ng/ml)</td>
<td>5.71 ± 0.36</td>
<td>11.43 ± 0.69</td>
<td>10.14 ± 0.34</td>
<td>9.14 ± 0.34</td>
<td>7.71 ± 0.36</td>
<td>9.14 ± 0.34</td>
<td>8.00 ± 0.38</td>
</tr>
<tr>
<td>CA 19–9 (U/ml)</td>
<td>18.86 ± 2.09</td>
<td>61.00 ± 3.48</td>
<td>54.57 ± 3.23</td>
<td>47.86 ± 2.44</td>
<td>32.71 ± 2.52</td>
<td>48.29 ± 2.51</td>
<td>41.86 ± 2.42</td>
</tr>
<tr>
<td>TPA (ng/ml)</td>
<td>1.17 ± 0.13</td>
<td>2.29 ± 0.05</td>
<td>2.03 ± 0.07</td>
<td>1.89 ± 0.03</td>
<td>1.53 ± 0.10</td>
<td>1.81 ± 0.08</td>
<td>1.69 ± 0.07</td>
</tr>
<tr>
<td>LDH (IU/L)</td>
<td>155.00 ± 6.37</td>
<td>238.43 ± 5.14</td>
<td>226.00 ± 5.15</td>
<td>217.86 ± 4.01</td>
<td>199.71 ± 3.36</td>
<td>211.14 ± 3.36</td>
<td>201.00 ± 3.39</td>
</tr>
</tbody>
</table>

All values were expressed as mean ± SE. Differences were considered significant at P<0.05.

Table (4) **Liver function in different treated groups**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
<th>Group E</th>
<th>Group F</th>
<th>Group G</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (IU/L)</td>
<td>27.86 ± 4.01</td>
<td>304.29 ± 16.16</td>
<td>224.29 ± 8.41</td>
<td>175.71 ± 8.41</td>
<td>124.29 ± 8.41</td>
<td>202.14 ± 8.30</td>
<td>152.14 ± 8.30</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>90.71 ± 13.11</td>
<td>394.29 ± 16.88</td>
<td>325.71 ± 8.41</td>
<td>271.43 ± 8.29</td>
<td>195.71 ± 16.35</td>
<td>252.86 ± 8.30</td>
<td>206.43 ± 12.14</td>
</tr>
<tr>
<td>ALP (IU/L)</td>
<td>63.57 ± 10.45</td>
<td>187.14 ± 19.70</td>
<td>167.86 ± 11.54</td>
<td>140.00 ± 9.82</td>
<td>122.14 ± 8.72</td>
<td>142.86 ± 10.11</td>
<td>130.00 ± 9.70</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>3.87 ± 0.27</td>
<td>2.59 ± 0.25</td>
<td>2.57 ± 0.16</td>
<td>2.89 ± 0.16</td>
<td>3.37 ± 0.16</td>
<td>2.83 ± 0.15</td>
<td>3.13 ± 0.15</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)</td>
<td>0.97 ± 0.07</td>
<td>1.84 ± 0.08</td>
<td>1.73 ± 0.06</td>
<td>1.54 ± 0.06</td>
<td>1.16 ± 0.10</td>
<td>1.59 ± 0.07</td>
<td>1.33 ± 0.05</td>
</tr>
</tbody>
</table>

All values were expressed as mean ± SE. Differences were considered significant at P<0.05.

Table (5) **Kidney function in different treated groups**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
<th>Group E</th>
<th>Group F</th>
<th>Group G</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUN (mg/dL)</td>
<td>18.00 ± 1.13</td>
<td>21.71 ± 1.36</td>
<td>26.86 ± 0.40</td>
<td>19.57 ± 1.41</td>
<td>18.29 ± 1.15</td>
<td>23.00 ± 0.38</td>
<td>18.57 ± 1.11</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>0.59 ± 0.07</td>
<td>1.36 ± 0.15</td>
<td>1.27 ± 0.16</td>
<td>1.00 ± 0.07</td>
<td>0.61 ± 0.07</td>
<td>1.19 ± 0.06</td>
<td>0.73 ± 0.07</td>
</tr>
</tbody>
</table>

All values were expressed as mean ± SE. Differences were considered significant at P<0.05.

**Figure 3:** Histopathological analysis of splenic sections stained with H & E. Group A: Weak expansion of red bulb. Group B: marked expansion of red bulb due to congestion and small uniform lymphoid follicles. Group C: congestion and atrophic lymphoid follicles. Group D: marked expansion of red bulb due to congested atrophic lymphoid follicles. Group E: moderate expansion of red bulb due to congestion and hyperplastic lymphoid follicles. Group F: marked expansion of red bulb due to congestion. Group G: expansion of red bulb due to congestion and atrophic lymphoid follicles.
Discussion
Ehrlich carcinoma has been used to investigate the antitumor effects of numerous natural and synthetic chemical substances (David et al., 2019). Consequently, the present study aimed to examine the possible defensive, curative properties, hepatic and renal ameliorative role of vitamin B17 against Ehrlich ascites carcinoma in comparison with antitumor activities of cisplatin and oxaliplatin as anticancer drugs. In accordance, we evaluate the deleterious changes in tumor markers and antioxidant status, liver and kidney functions in EAC – bearing female rats. The current study revealed that i.p injection of Ehrlich cells induced a rapid increase in ascitic fluid volume in EAC bearing rats in untreated group (Group B) as shown in Figure 1. This come in agreement with Hackensellner and Hermanek (1958); Osman et al. (2015); Stroud et al. (1957) and Alotaibi et al. (2021); Funasaka et al. (2002); Hashem et al. (2020) who studied Ehrlich ascites tumors in rats and mice, respectively. Our results revealed that Ehrlich tumor-induced alterations in hematological parameters including decrease in RBCs count, Hb, PCV, and gradual
increase in PLT and WBCs, as well induced changes in MCV, MCH, and MCHC levels. These results are consistent with those reported by Agrawal et al. (2011); Mutar et al. (2019); Perveen et al. (2012). This could be explained by the suppressive influence of EAC on bone marrow erythropoiesis. However, observed the granulocytic leucocytosis may be due to development of stress in response to increased fluid ascites cells or acute inflammatory response (AL-Mashhadani et al., 2018). Data of current study demonstrated marked (P<0.05) reduction in SOD and CAT activities and GSH content whereas elevation of MDA content in EAC bearing rats as compared with that of normal control rats. In accordance with our results, Haldar et al. (2010) recorded depletion of SOD activity and GSH level coincided with elevated MDA level in tumor-bearing animals. Our findings indicated that EAC induces significant (P<0.05) increase in tumor markers including AFP, CEA, CA 19-9, TPA and LDH. Alpha-fetoprotein is a commonly used tumor marker for diagnosis of hepatocellular carcinoma (Tangkijvanich et al., 2000) as well as estimation of tumor size (Qin and Tang, 2002). Similar results were also obtained by Perkins et al. (2003) who reported that, an increase in CEA and CA19-9 levels is associated with adenocarcinoma, especially colorectal cancer. Also, elevated TPA levels can also be detected in some benign events such as liver failure, renal failure, gestation, generalized infection, and diabetes mellitus (Tramonti et al., 2000). Further, Samudrala et al. (2015) observed that intraperitoneal inoculation of EAC cells is associated with a significant (P<0.05) increase in serum activity of LDH which could be attributed to hepatocellular damage induced by EAC. Ehrlich carcinoma caused abnormalities in liver functions which is indicated by increased activities of serum enzymes ALT, AST and ALP beside marked elevation in total bilirubin level and diminished albumin level compared to normal control group. The current results come in agree with results obtained by Haldar et al. (2010). Our findings indicated that the observed impairment of liver functions could be a direct consequence of both disruption of cellular redox balance together with cancer development. It has been reported that increased lipid peroxidation and inhibition of GSH content, catalase and SOD activity led to liver and kidney
dysfunction (Borges et al., 2006). Moreover, these data are supported by histopathological examination of hepatic sections which revealed increased number of necrotic hepatocytes with deeply pyknotic nuclei, congestion associated with brown pigment deposition and thickening of wall on the central vein. Similar results were reported by Ali et al. (2015) and Badr et al. (2011).

Besides, Ehrlich tumor has been shown to induce kidney injury and negatively influence renal function. This is evidenced by increased levels of BUN and creatinine. Similarly, Habib et al. (2010); Khanam et al. (2010) demonstrated that EAC led to elevation of serum urea, creatinine potassium and chloride ions whereas decreased sodium ions. Histopathological examination of kidney sections showed marked degeneration in glomeruli and some parts of the urinary tubules in kidney sections in EAC-bearing group. These results are in harmony with Abd Eldaim et al. (2019a); Badr et al. (2011); El-Wahab and Fouda (2009); Medhat et al. (2017); Salem et al. (2011) who recorded histopathological alteration in renal tissue which varied from cellular infiltration to degenerated renal tubules and atrophied glomeruli following induction of EAC.

The adverse effects of cisplatin on hematological parameters were demonstrated as significantly (P<0.05) diminished RBCs and platelets counts with subsequent reduction in the values of Hb%, MCV, MCH, MCHC and PCV together with elevation of WBCs. Previous studies proposed that there is a reasonable relationship between cisplatin treatment and occurrence of anemia. This could be clarified via various mechanisms including increment of RBCs osmotic fragility or deterioration of cells of bone marrow. Consequently, cisplatin intoxication could result in anemia due to either disruption of erythropoiesis, prohibition of hematopoietic tissues activity or hastened RBCs breakdown due to alteration of membrane permeability of RBCs (Yuan et al., 2014). Furthermore, Marković et al. (2011) showed that apart from the diminished RBC count, prolonged cisplatin application could trigger a decline in platelets count and an elevation in WBCs count of rats. The reduction in platelets count could arise from inhibition of bone marrow activity by cisplatin or might be due to reduced synthesis or elevated consumption of platelets or due to the excess platelets aggregation (Sirag,
In this consequence, Olas et al. (2005) stated that cisplatin induces oxidative stress (OS) in human platelets and lymphocytes, which might negatively affect their life span, and subsequently trigger apoptosis, thus decreasing these cells number in the blood. Epitoxicity induced by cisplatin is detected by the alterations of the histological, biochemical and molecular parameters (Attyah and Ismail, 2012; El-Sayyad et al., 2009; Karadeniz et al., 2011). In the current experiment, the cisplatin injected rats showed elevation of activities of serum enzymes of ALT, AST, ALP together with depression of serum level of albumin when compared with negative control group. As the elevation in the serum activity of liver cytoplasmic enzyme, ALT indicates necrotic lesions in the hepatic cells. On the other hand, the decline in serum albumin level indicates that there was a deterioration in both synthetic and excretory activities of the liver (El-Sharaky et al., 2009). Histopathological examination of hepatic tissue in cisplatin treated groups are in line with the previously observed parameters and histological alterations in hepatic sections of this group. The current results come in agreement with Abdelmeguid et al. (2010) who manifested marked alterations in hepatic tissue following cisplatin treatment. Our study revealed marked increment of serum AFP level in cisplatin treated group compared to the control. Numerous studies have revealed that serum AFP concentration elevates in response to exposure to hepatotoxic or hepatocarcinogenic agents (Abass et al., 2018). However, in the current study, cisplatin treated rats exhibited a decrement in the levels of tumor markers compared to untreated EAC rats. This could be explained by the anticancer capabilities of cisplatin. The current results are in accordance with results of Abdel-Hamid et al. (2011).

It has been documented that cisplatin-induced hepatotoxicity and nephrotoxicity are related to reactive oxygen species (ROS). The elevated ROS attacks the membrane lipids generating the lipid peroxides, which are manifested by increased MDA. The increased MDA level depleted vitamin E, vitamin C, and GSH (Abdel-Raheem et al., 2009). Data from the current study revealed that depletion of GSH, SOD and CAT levels after cisplatin administration might be in response to cisplatin induced oxidative stress. The observed elevation of hepatic enzymes together with increased
total bilirubin confirm cisplatin hepatotoxicity. This was augmented by pathological alteration in hepatocyte architecture in this group. In addition, it has been documented that cisplatin induce a renal tubular damage which is manifested by impaired reabsorption which is characterized by reduced glomerular filtration rate, increased serum creatinine and blood urea concentrations (Hanigan and Devarajan, 2003; Miller et al., 2010). In this study, histopathological and biochemical evaluation of cisplatin-induced structural alterations and degree of functional alterations in the kidneys were performed in order to determine cisplatin-induced nephrotoxicity. Also, histopathological evaluation of renal section of cisplatin treated rats (Group C) augmented cisplatin-induced nephrotoxic effect.

Results of the current study showed development of anemia following oxaliplatin treatment. Evaluation of blood from oxaliplatin-treated rats indicated decreased WBC count and macrocytic anemia. Oxaliplatin is well known to be deleterious to RBC (Fazio et al., 2015) and could directly interact with Hb (Mandal et al., 2004). Later on, oxaliplatin interaction with hemoglobin has been documented (Potenzieri et al., 2020). Oxaliplatin induced thrombocytopenia occurs mainly due to suppression of bone marrow in a manner similar to other compounds related to the platinum family (Curtis et al., 2006).

The current study revealed that oxaliplatin could induce OS. This is obvious in context of the significantly increased levels of MDA, as well as the markedly decreased antioxidant defense mechanisms (CAT, SOD, and GSH). These results are in harmony with those reported by Robinson et al. (2013). Alterations in hepatic SOD and GSH levels may be explained as a consequence to protein oxidation induced by oxaliplatin treatment in liver mitochondria which results in elevation of superoxide production which in turn impair liver defense mechanism against OS induced by oxaliplatin (Fernandez et al., 2005).

Chan et al. (2009) demonstrated the predictive and monitoring roles of the AFP in hepatic ascites carcinoma (HAC) in rats receiving oxaliplatin-based chemotherapy with extrahepatic spreading. They found significant elevation in AFP after i.p oxaliplatin administration. They suggested that integration of AFP response into the criteria which evaluate treatment. Such consequence
should be considered in both clinical practice and trials of novel chemotherapeutic agents for treating hepatic carcinoma. In this study, a reported increase in the levels of CEA & CA 19-9 after treating rats with oxaloplatin. Oxaliplatin has been confirmed to induce inflammatory response, which sounds to be one of the mechanisms of its toxicity. Moreover, elevated CEA level has been correlated with development of inflammation and this was found to agree with the results obtained by Kwon et al. (2018).

It has been reported that oxaliplatin causes elevation of ALT and AST activities and level of total bilirubin (Gurzu et al., 2013). The increased production of bilirubin could be due to the suppressed bilirubin metabolism or obstruction of the bile ducts. Hepatotoxicity induced by oxaliplatin is mainly manifested as hepatic steatosis beside sinus injury (Rubbia-Brandt et al., 2010). Furthermore, El Chediak et al. (2018) has manifested that Oxaliplatin hepatotoxicity is most likely associated with splenomegaly in addition to triggering systemic inflammation and elevation of OS.

Unlike cisplatin, oxaliplatin, has been documented to exerts minimal impact on humans and rat kidney (Launay-Vacher et al., 2008; Simpson et al., 2003). This is supported in our study by the suppressed urea and creatinine levels in oxaliplatin treated group more than control positive and cisplatin treated groups. In a study of the pharmacokinetic and toxicodynamic relationships of platinum compounds, it has been documented that the cause for the different tendency of cisplatin and oxaliplatin to development nephrotoxicity is mainly pharmacokinetic in origin besides the total clearance of oxaliplatin was the greatest among the latest platinum compounds (Hanada et al., 2010).

According to our result, hematological parameters were almost restored back to normal range when EAC rats were treated with VB17. Also, VB17 was found to improve WBCs and PLT count efficiently. The MCV, MCH, and MCHC levels were observed to be in the normal range. According to AL-Mashhadani et al. (2018) VB17 treatment depleted the elevations in AFP levels. This was also emphasized by the findings of Aldubayan et al. (2019); Bruce et al. (2008); Choi and Kakar (2017) who documented that the elevation of serum AFP level might indicate hepatic inflammatory activity and could be
accompanied by elevation of AST, ALT, and ALP enzyme activities. Additionally, Makarević et al. (2016) reported that VB17 possesses a different mechanism through its acquisition on the primary tumor cell’s integrin structure which suggests the ability of vitamin B17 to delay the EAC growth in rats.

The current study demonstrated that VB17 was efficiently controlled antioxidant defense system via elevating the levels of catalase, GSH and SOD, whereas decreasing the levels of MDA which indicates antioxidant properties and free-radical scavenging capability of vitamin B17 extract. From these results, we can suggest that vitamin B17 have powerful effects for the treatment of liver cancer when compared with control positive groups.

It was evidenced that VB17 has hepatic ameliorative potential against EAC, which is emphasized by decline of serum AST, ALT, and ALP and elevations of albumin and reduction in total bilirubin levels. The regulation of AST and ALT activities by VB17 supports the possibility that hepatoprotective effect of VB17 occurs through enhancement of antioxidant defense system as together with its scavenging and antioxidant potentials (AL-Mashhadani et al., 2018). Badr et al. (2011) reported VB17 could effectively alleviate liver damage through maintaining plasma membrane integrity thereby repressing leakage of enzyme via membranes and consequently exhibit hepatoprotective activity. This might be a reason for restoration of activities of enzymes after administration of Vitamin B17.

Vitamin B17 also exerts renal ameliorative capacity against EAC induced renal injury in female rats. This is obvious by reduced levels serum urea and creatinine in this group. Furthermore, our results were consistent with Salem et al. (2011) who reported that the EAC results in renal dysfunction and elevates serum urea and creatinine levels. These effects were reversed following VB17 treatment. Moreover, Juengel et al. (2016) reported that VB17 could inhibit the kidney cell carcinoma development in rats.

**Conclusion**

The present study demonstrated reduced levels of tumor markers, liver enzymes, BUN, creatinine and MDA and enhanced antioxidant indicators (CAT, GSH and SOD) in the EAC group treated with vitamin B17. This indicates the antineoplastic and antioxidant properties exerted by vitamin B17 and suggests that vitamin B17 can be used as a reliable
and novel therapy for EAC or used in combination with chemotherapeutic agents to overcome their side effects.

References


Hackensellner, H.A.; Hermanek, P. (1958): Influenceability of subcutaneous transplantation of Ehrlich mouse...


Olas, B.; Wachowicz, B.; Majsterek, I.; Blasiak, J. (2005): Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and


التقييم الكيميائي الحيوي لنشاط فيتامين ب17 للمضادات للأورام بمفرده أو بالاشتراك مع الأدوية التي تحتوي على البلاتين ضد سرطان استسقاء إيرليخ في إناث الجرذان

أشرف بركات سيد، شريف يوسف صالح، إبراهيم عاشور إبراهيم، ياسمينا كمال محمود، مروة أحمد البلتاجي
قسم الكيمياء الحيوية، كلية الطب البيطري، جامعة قناة السويس

ترتبط أدوية العلاج الكيميائي بالعديد من الآثار الجانبية. وبالتالي، فإن الكثير من الأبحاث تهتم باكتشاف المركبات الكيميائية النباتية الطبيعية التي يمكن استخدامها في الوقاية أو علاج السرطان. استُخدم نموذج سرطان استسقاء إيرليخ (EAC) للإشارة إلى فاعلية بعض العلاجات الكيميائية والمصادر النباتية ضد السرطان نتيجة تشابهها مع الأورام التي تصيب الإنسان. أجريت هذه الدراسة للتحقق من التأثيرات مضادة للأورام ومضادات الأكسدة لفيتامين ب17 بجانب الأدوية التي تحتوي على البلاتين ومن أجل دراسة التأثيرات الجانبية. توزيع الحيوانات على سبع مجموعات (N = 7) على النحو التالي:

- المجموعة أ: جرذان مصابة بالسرطان
- المجموعة ب: جرذان مصابة بالسرطان تم علاجها بواسطة السيبلاتين
- المجموعة ج: جرذان تم علاجهم بواسطة السيبلاتين وذهاولة ب17
- المجموعة د: جرذان مصابة بالسرطان وعلاجهم بواسطة السيبلاتين وذهاولة ب17
- المجموعة ه: جرذان مصابة بالسرطان تم علاجهم بواسطة السيبلاتين وذهاولة ب17
- المجموعة ف: جرذان مصابة بالسرطان تم علاجهم بواسطة السيبلاتين وذهاولة ب17
- المجموعةتفاصيل: مجموعات A-G تم استخدام عدد من الاختبارات الكيميائية لقياس مستويات حمض LDH و الكرياتينين و BUN و الإجمالي البيليروبين في المصل جنبًا إلى جنب مع تحليل الأنسجة المرضية لقياس النشاط مضاد للأورام والآثار الجانبية لأي دواء مصرف.

أظهرت النتائج أن إعطاء فيتامين ب17 بمفرده أو بالاشتراك مع السيبلاتين أو الذهاولة أدى إلى انخفاض مستوى البيليروبين بالإضافة إلى تحسن مؤشرات مضادات الأكسدة مثل CAT و SOD. بالإضافة إلى أن ازدياد-levels of LDH و الكرياتينين و BUN و الإجمالي البيليروبين في المصل جنبًا إلى جنب مع تحليل الأنسجة المرضية لقياس النشاط مضاد للأورام والآثار الجانبية لأي دواء مصرف.

أظهرت النتائج أن إعطاء فيتامين ب17 بمفرده أو بالاشتراك مع السيبلاتين أو الذهاولة أدى إلى انخفاض مستوى البيليروبين بالإضافة إلى تحسن مؤشرات مضادات الأكسدة مثل CAT و SOD. بالإضافة إلى أن ازدياد-levels of LDH و الكرياتينين و BUN و الإجمالي البيليروبين في المصل جنبًا إلى جنب مع تحليل الأنسجة المرضية لقياس النشاط مضاد للأورام والآثار الجانبية لأي دواء مصرف.

أظهرت النتائج أن إعطاء فيتامين ب17 بمفرده أو بالاشتراك مع السيبلاتين أو الذهاولة أدى إلى انخفاض مستوى البيليروبين بالإضافة إلى تحسن مؤشرات مضادات الأكسدة مثل CAT و SOD. بالإضافة إلى أن ازدياد-levels of LDH و الكرياتينين و BUN و الإجمالي البيليروبين في المصل جنبًا إلى جنب مع تحليل الأنسجة المرضية لقياس النشاط مضاد للأورام والآثار الجانبية لأي دواء مصرف.